Charise Gleason

2.3k total citations · 1 hit paper
46 papers, 1.5k citations indexed

About

Charise Gleason is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Charise Gleason has authored 46 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Hematology, 28 papers in Oncology and 27 papers in Molecular Biology. Recurrent topics in Charise Gleason's work include Multiple Myeloma Research and Treatments (39 papers), Protein Degradation and Inhibitors (24 papers) and Cancer Treatment and Pharmacology (14 papers). Charise Gleason is often cited by papers focused on Multiple Myeloma Research and Treatments (39 papers), Protein Degradation and Inhibitors (24 papers) and Cancer Treatment and Pharmacology (14 papers). Charise Gleason collaborates with scholars based in United States, Canada and India. Charise Gleason's co-authors include Amelia Langston, Christopher R. Flowers, Kenneth V. I. Rolston, Eric J. Bow, Douglas K. Hawley, Sagar Lonial, Jonathan L. Kaufman, Jennie R. Crews, Randy Taplitz and Erin B. Kennedy and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Charise Gleason

41 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update

2018 356 citations Randy Taplitz, Erin B. Kennedy et al. Journal of Clinical Oncology profile →

Peers

Charise Gleason

ONCOL

HEMAT

EPIDE

Domenico Pastore Italy

G Todeschini Italy

Antonio Spadea Italy

M Kalaycio United States

Rasim Gucalp United States

Erika Borlenghi Italy

Eliana Zuffa Italy

Carmen Di Grazia Italy

Steven Trifilio United States

Hans‐Heinrich Wolf Germany

Domenico Pastore Italy

Charise Gleason

379 ×0.4

ONCOL

582 ×0.9

HEMAT

216 ×0.5

205 ×0.6

EPIDE

119 ×0.5

Citations per year, relative to Charise Gleason Charise Gleason (= 1×) peers Domenico Pastore

Countries citing papers authored by Charise Gleason

Since Specialization

Citations

This map shows the geographic impact of Charise Gleason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charise Gleason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charise Gleason more than expected).

Fields of papers citing papers by Charise Gleason

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charise Gleason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charise Gleason. The network helps show where Charise Gleason may publish in the future.

Co-authorship network of co-authors of Charise Gleason

This figure shows the co-authorship network connecting the top 25 collaborators of Charise Gleason. A scholar is included among the top collaborators of Charise Gleason based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charise Gleason. Charise Gleason is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kaufman, Jonathan L., Roberto Mina, Jatin J. Shah, et al.. (2020). Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 20(12). 797–803. 5 indexed citations

Mıkhael, Joseph, Kimberly Noonan, Beth Faiman, et al.. (2020). Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. Clinical Lymphoma Myeloma & Leukemia. 20(6). 351–357. 19 indexed citations

Kaufman, Jonathan L., Roberto Mina, Andrzej Jakubowiak, et al.. (2019). Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood Cancer Journal. 9(1). 3–3. 44 indexed citations

Faiman, Beth, et al.. (2019). Development of a Participatory Patient Decision Aid for Patients with Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 19(10). e348–e349. 1 indexed citations

Mina, Roberto, Nisha S. Joseph, Jonathan L. Kaufman, et al.. (2018). Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer. 125(3). 416–423. 34 indexed citations

Taplitz, Randy, Erin B. Kennedy, Eric J. Bow, et al.. (2018). Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. Journal of Clinical Oncology. 36(14). 1443–1453. 211 indexed citations

Joseph, Nisha S., Charise Gleason, Leonard T. Heffner, et al.. (2017). Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM). Blood. 130. 3139–3139.

Noonan, Kimberly, et al.. (2017). Distress, Fatigue, and Sexuality: Understanding and Treating Concerns and Symptoms in Patients With Multiple Myeloma. Clinical journal of oncology nursing. 21(5). 7–18. 7 indexed citations

Nooka, Ajay K., et al.. (2016). Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients. Blood. 128(22). 492–492. 20 indexed citations

10.

Nooka, Ajay K., Jonathan L. Kaufman, Madhusmita Behera, et al.. (2015). Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs). Blood. 126(23). 5344–5344. 1 indexed citations

11.

Kaufman, Jonathan L., Charise Gleason, Lawrence Boise, et al.. (2014). Bortezomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (V-DCEP) for the Treatment of Multiple Myeloma. Blood. 124(21). 2139–2139. 10 indexed citations

12.

Nooka, Ajay K., Donald Harvey, Jonathan L. Kaufman, et al.. (2013). Using Serum Free Light Chain (SFLC) Ratio and Serum Protein Electrophoresis (SPEP) As a Substitute For 24-Hour Urine Studies In Myeloma Patients. Blood. 122(21). 5358–5358. 2 indexed citations

13.

Kaufman, Jonathan L., Amelia Langston, Leonard T. Heffner, et al.. (2013). Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 28(3). 690–693. 142 indexed citations

14.

Nooka, Ajay K., Amelia Langston, Edmund K. Waller, et al.. (2013). Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).. Journal of Clinical Oncology. 31(15_suppl). 8540–8540. 2 indexed citations

15.

Gleason, Charise, et al.. (2011). Treatment of severe neutropenia with high-dose pyridoxine in a patient with chronic graft versus host disease and squamous cell carcinoma: a case report. Journal of Medical Case Reports. 5(1). 372–372. 4 indexed citations

16.

Li, Jie, Mary Jo Lechowicz, Amelia Langston, et al.. (2011). Effectiveness and cost analysis of “just‐in‐time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion. 51(10). 2175–2182. 85 indexed citations

17.

Nooka, Ajay K., Charise Gleason, & Sagar Lonial. (2010). Improving Induction Therapy in Multiple Myeloma. Current Hematologic Malignancy Reports. 5(3). 119–128. 1 indexed citations

18.

Gleason, Charise, Ajay K. Nooka, & Sagar Lonial. (2009). Supportive Therapies in Multiple Myeloma. Journal of the National Comprehensive Cancer Network. 7(9). 971–979. 4 indexed citations

19.

Kaufman, Jonathan L., Charise Gleason, & Sagar Lonial. (2009). Treatment of relapsed and refractory myeloma. Current Hematologic Malignancy Reports. 4(2). 99–107. 3 indexed citations

20.

Johnson, Donna B., David L. Eaton, P Wahl, & Charise Gleason. (2001). Public health nutrition practice in the United States. Journal of the American Dietetic Association. 101(5). 529–534. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact